Success Metrics

Clinical Success Rate
70.8%

Based on 17 completed trials

Completion Rate
71%(17/24)
Active Trials
1(3%)
Results Posted
135%(23 trials)
Terminated
7(21%)

Phase Distribution

Ph not_applicable
5
15%
Ph early_phase_1
3
9%
Ph phase_1
12
35%
Ph phase_2
7
21%
Ph phase_4
7
21%

Phase Distribution

15

Early Stage

7

Mid Stage

7

Late Stage

Phase Distribution34 total trials
Early Phase 1First-in-human
3(8.8%)
Phase 1Safety & dosage
12(35.3%)
Phase 2Efficacy & side effects
7(20.6%)
Phase 4Post-market surveillance
7(20.6%)
N/ANon-phased studies
5(14.7%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

53.1%

17 of 32 finished

Non-Completion Rate

46.9%

15 ended early

Currently Active

1

trials recruiting

Total Trials

34

all time

Status Distribution
Active(1)
Completed(17)
Terminated(15)
Other(1)

Detailed Status

Completed17
Withdrawn8
Terminated7
unknown1
Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials
34
Active
1
Success Rate
70.8%
Most Advanced
Phase 4

Trials by Phase

Early Phase 13 (8.8%)
Phase 112 (35.3%)
Phase 27 (20.6%)
Phase 47 (20.6%)
N/A5 (14.7%)

Trials by Status

unknown13%
completed1750%
withdrawn824%
active_not_recruiting13%
terminated721%

Recent Activity

1 active trials
Showing 5 of 34
active_not_recruitingphase_2

Phase II Trial to Modulate Intermediate Endpoint Biomarkers in Former and Current Smokers

NCT03598309
withdrawnphase_1

QUILT-3.047: NANT Head and Neck Squamous Cell Carcinoma (HNSCC) Vaccine: Combination Immunotherapy in Subjects With HNSCC Who Have Progressed on or After Chemotherapy and PD-1/PD-L1 Therapy

NCT03169764
withdrawnphase_1

QUILT-3.052: NANT Non-Hodgkin Lymphoma (NHL) Vaccine: Combination Immunotherapy in Subjects With Relapsed CD20-positive NHL

NCT03169790
withdrawnphase_1

QUILT-3.048: NANT Urothelial Cancer Vaccine: Combination Immunotherapy in Subjects With Urothelial Cancer Who Have Progressed on or After Chemotherapy and PD-1/PD-L1 Therapy

NCT03197571
withdrawnphase_1

QUILT-3.050: NANT Colorectal Cancer (CRC) Vaccine: Combination Immunotherapy in Subjects With Recurrent or Metastatic CRC

NCT03169777
View all 34 trials

Clinical Trials (34)

Showing 20 of 34 trialsScroll for more
NCT03598309Phase 2

Phase II Trial to Modulate Intermediate Endpoint Biomarkers in Former and Current Smokers

Active Not Recruiting
NCT03169764Phase 1

QUILT-3.047: NANT Head and Neck Squamous Cell Carcinoma (HNSCC) Vaccine: Combination Immunotherapy in Subjects With HNSCC Who Have Progressed on or After Chemotherapy and PD-1/PD-L1 Therapy

Withdrawn
NCT03169790Phase 1

QUILT-3.052: NANT Non-Hodgkin Lymphoma (NHL) Vaccine: Combination Immunotherapy in Subjects With Relapsed CD20-positive NHL

Withdrawn
NCT03197571Phase 1

QUILT-3.048: NANT Urothelial Cancer Vaccine: Combination Immunotherapy in Subjects With Urothelial Cancer Who Have Progressed on or After Chemotherapy and PD-1/PD-L1 Therapy

Withdrawn
NCT03169777Phase 1

QUILT-3.050: NANT Colorectal Cancer (CRC) Vaccine: Combination Immunotherapy in Subjects With Recurrent or Metastatic CRC

Withdrawn
NCT03175666Phase 1

QUILT-3.049: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Combination Immunotherapy in Subjects With TNBC Who Have Progressed on or After Anthracycline-based Chemotherapy

Withdrawn
NCT03169738Phase 1

QUILT-3.044: NANT Non-small Cell Lung Cancer (NSCLC) Vaccine: Combination Immunotherapy in Subjects With NSCLC Who Have Progressed After Treatment With PD-1/PD-L1 Inhibitors

Withdrawn
NCT05281562Phase 2

Immunonutrition for Diabetic Foot Ulcers

Terminated
NCT03329248Phase 1

QUILT-3.060: NANT Pancreatic Cancer Vaccine: Molecularly Informed Integrated Immunotherapy in Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy

Terminated
NCT03387098Phase 1

QUILT-3.070:Pancreatic Cancer Vaccine: Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy

Terminated
NCT00743197Not Applicable

Women With Chest Pain and Normal Coronary Arteries Study

Terminated
NCT04308889Early Phase 1

Pro-Resolving Mediators in Acute Inflammation in Humans

Completed
NCT00959842Phase 1

Effects of Lovaza on Lipoprotein Composition and Function in Mild Hypertriglyceridemia

Completed
NCT01823991Early Phase 1

COGNUTRIN in Breast Cancer Survivors

Completed
NCT01041521Phase 4

The Impact of Omega Three Fatty Acids on Vascular Function in HIV

Completed
NCT00795717Phase 4

Human Immunodeficiency Virus (HIV), Arterial Dysfunction, Lipids, Lovaza (HALO) Trial

Completed
NCT02010359Phase 4

Fish Oils and Adipose Inflammation Reduction

Completed
NCT00577590Not Applicable

Effects of Fatty Acid Delivery on Heart Metabolism and Function in Type 2 Diabetes (T2DM

Completed
NCT00569686Not Applicable

Lovaza Therapy of Peripheral Arterial Disease

Withdrawn
NCT01155336Phase 1

The Effects of Lovaza® in Acute Myocardial Infarction

Terminated

Drug Details

Intervention Type
DRUG
Total Trials
34